Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 confirmatory study of KC-8025 in primary biliary cholangitis with inadequate response to or intolerance of ursodeoxycholic acid
jRCT2071240075Phase 3Active, not recruiting
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of seladelpar in primary biliary cholangitis (PBC) (2 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoint: Composite biochemical response at Week 52. Started Mar 2025; status: active, not recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2071240075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240075.